We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection solution
Indication
For the treatment of adult and paediatric patients with primary mediastinal B-cell lymphoma